Children's Oncology Group Statistics and Data Center

儿童肿瘤学组统计和数据中心

基本信息

批准号：
10363675
负责人：
TODD A ALONZO
金额：
$ 923.46万
依托单位：
PUBLIC HEALTH INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-04-15 至 2023-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10363675
关键词：
1 year old Acute Acute Myelocytic Leukemia Adolescent Advanced Development Australia Biology Brain Stem Glioma Canada Cancer Center Cancer Patient Cancer Survivor Caring Cause of Death Cell Therapy Child Child Support Childhood Childhood Cancer Treatment Childhood Leukemia Clinical Clinical Research Clinical Trials Clinical Trials Cooperative Group Clinical Trials Design Collaborations Collection Communities Companions Complication Country Data Diagnosis Disease Ensure Family Foundations Functional disorder Generations Genomics Goals Hormonal Immunotherapy Industry Infrastructure Institution Interdisciplinary Study Knowledge Laboratories Late Effects Malignant Childhood Neoplasm Malignant Neoplasms Methods Mission Molecular Morbidity - disease rate National Cancer Institute National Clinical Trials Network Neuroblastoma New Zealand Organ Outcome Patients Pediatric Hospitals Pediatric Oncology Group Pharmaceutical Preparations Population Heterogeneity Population Research Prognosis Quality of life Rare Diseases Reporting Research Research Personnel Science Second Primary Cancers Survival Rate Survivors Time Tissues Translational Research United States Universities Work anticancer research base cancer therapy chemotherapy childhood cancer survivor data centers data management data sharing density design experience functional outcomes health related quality of life high risk improved improved outcome innovation member mortality multidisciplinary novel novel therapeutic intervention organizational structure programs reproductive small molecule statistics survivorship translational clinical trial translational scientist translational study trial design

项目摘要

PROJECT SUMMARY Since the introduction of chemotherapy for the treatment of childhood leukemia more than 60 years ago, the prognosis of childhood cancer has improved dramatically. The overall 5-year survival rate for childhood cancers, many of which were uniformly fatal in the pre-chemotherapy era, is now 84%. Progress for a number of childhood cancers, however, has been limited, with approximately 50% of children with acute myelogenous leukemia, 50% of children with high-risk neuroblastoma, and more than 90% of children with brainstem glioma, still succumbing to their disease. In the US, cancer remains the leading cause of death from disease in children greater than one year of age. Moreover, the late effects of cancer treatment, including permanent organ and tissue damage, hormonal and reproductive dysfunction and second cancers, are of special concern, with more than 40% of the estimated 360,000 survivors of childhood cancer experiencing a significant health related quality of life complication from childhood cancer and its treatment. Thus, despite our advances, development of new therapeutic approaches must be a priority for childhood cancer basic, translational and clinical researchers. The Children’s Oncology Group (COG), the world’s largest organization devoted exclusively to childhood and adolescent cancer research, was founded 17 years ago. The COG’s multidisciplinary research team, comprised of more than 9,000 members, conducts research at more than 220 leading children’s hospitals, universities, and cancer centers. This proposal is for COG, as part of the National Cancer Institute’s (NCI) National Clinical Trials Network (NCTN), to continue its collaborative research work that supports the mission of improving the outcome for all children with cancer. The COG will design and conduct clinical-translational studies for children with cancer that builds on an increasing understanding of the molecular basis for pediatric malignancies and has the highest potential to improve the outcome. Using innovative clinical trial designs suitable for the study of rare diseases, we will study novel therapeutic approaches including but not limited to targeted small molecule drugs, immunotherapies and cellular therapies. The COG research portfolio importantly also includes clinical trials focused on improving the quality of life children with cancer and survivors. As more than 90% of children diagnosed with cancer in the US are treated at COG member institutions, the COG has the ability to offer a diverse population of children with cancer and their families the opportunity to participate in innovative research. This research effort includes allowing for collection and annotation of biospecimens from all children with cancer, providing the foundation for discovery and accelerating the most promising research efforts conducted in laboratories around the world. The proposal is for support of the COG Network Statistics and Data Management Center which collaborates with COG scientific leaders to design, conduct, analyze and report the results of clinical-translational trials for the treatment of childhood cancers.

项目概要自从 60 多年前引入化疗治疗儿童白血病以来，儿童癌症的预后显着改善儿童癌症的总体 5 年生存率其中许多在化疗前时代都是致命的，但现在有 84% 的儿童出现了进展。然而，癌症的发生受到限制，大约 50% 的儿童患有急性髓性白血病，50% 的高危神经母细胞瘤儿童和超过 90% 的脑干胶质瘤儿童仍在死亡在美国，癌症仍然是导致 1 岁以上儿童死亡的主要原因。此外，癌症治疗的后期影响，包括永久性器官和组织损伤，荷尔蒙和生殖功能障碍以及第二种癌症受到特别关注，超过 40% 估计有 360,000 名儿童癌症幸存者经历了与健康相关的显着生活质量因此，尽管我们取得了进步，但新的治疗方法仍在开发中。治疗方法必须成为儿童癌症基础、转化和临床研究人员的首要任务。儿童肿瘤学小组 (COG)，世界上最大的专门致力于儿童和癌症研究的组织 COG 的多学科研究团队成立于 17 年前。拥有 9,000 多名会员，在 220 多家领先的儿童医院、大学和该提案针对 COG，作为国家癌症研究所 (NCI) 国家临床试验的一部分。网络（NCTN），继续其协作研究工作，支持改善结果的使命针对所有癌症儿童，COG 将为癌症儿童设计并开展临床转化研究。它建立在对儿科恶性肿瘤分子基础的日益了解的基础上，并且具有最高的使用适合罕见疾病研究的创新临床试验设计的潜力，我们将研究新的治疗方法，包括但不限于靶向小分子药物，重要的是，COG 研究组合还包括临床试验。专注于改善癌症儿童和幸存者的生活质量超过 90% 的儿童。在美国被诊断患有癌症并在 COG 成员机构接受治疗时，COG 有能力提供不同的癌症儿童群体及其家人有机会参与创新研究。这项研究工作包括收集和注释所有癌症儿童的生物样本，为发现提供基础并加速最有前途的研究工作该提案旨在支持 COG 网络统计和数据管理。该中心与 COG 科学领导者合作设计、进行、分析和报告结果治疗儿童癌症的临床转化试验。